List of works - Philippe Flandre

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure

article

A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity

scientific article (publication date: 2013)

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study

scientific article

A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients

scientific article published on 10 February 2004

Accuracy of predictive ability measures for survival models.

scientific article published on 07 June 2017

Analyzing Plasma HIV-1 RNA Measurements as Multiple Recurrent Events in Clinical Trials

article

Anti-gp41 antibody levels reflect HIV viral suppression and cellular reservoir in long-term antiretroviral-treated trial participants

scientific article published on 01 May 2019

Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study.

scientific article published on 7 December 2017

Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

scientific article published on 25 October 2014

Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma

scientific article published on 2 May 2017

Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

article

Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 Substudy

article

Choice of effect measure in HIV randomized trials.

scientific article published on September 2015

Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients

scientific article published in January 2006

Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach

scientific article

Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy

scientific article

Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load

scientific article published on 26 August 2015

Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).

scientific article published on August 2005

Comparison of 48-week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimens: a systematic review and network meta-analysis

scientific article published on 13 July 2018

Confirmation of the low clinical effect of human herpesvirus-6 and -7 infections after renal transplantation

scientific article published in March 2012

Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients

scientific article published on 3 January 2015

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes

scientific article

Design of HIV noninferiority trials ⬇️

scientific article published on February 20, 2013

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey

scientific article published in May 2012

Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets

scientific article published in January 2010

Discussion by O'Quigley and Flandre

scientific article published on 13 June 2011

Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine

scientific article published on 27 September 2011

Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group?

scientific article

E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure

scientific article published in August 2012

Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study

scientific article published in November 2005

Effect of antiretroviral drugs on the quality of semen

scientific article published in August 2011

Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.

scientific article

Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data

scientific article published on 14 January 2015

Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen

scientific article

Estimating and comparing reduction in HIV-1 RNA in clinical trials using methods for interval censored data

scientific article

Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study

scientific article

Evidence for a major gene controlling susceptibility to tegumentary leishmaniasis in a recently exposed Bolivian population

scientific article

Factors Associated With Virological Failure in HIV-1–Infected Patients Receiving Darunavir/Ritonavir Monotherapy

article

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy

scientific article

Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir

scientific article

Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients

scientific article

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial

scientific article published on January 2011

Final analysis of the Trilège induction-maintenance trial: results at 18 months

scientific article published in March 2002

Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).

scientific article published in June 2005

Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials

scientific article published on 13 October 2008

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc

scientific article published on 11 June 2015

HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes

scientific article published on 25 November 2012

Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml

article

Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial

scientific article published on 18 March 2010

Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease

scientific article published in September 2008

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients

scientific article

Impact of pre-therapy viral load on virological response to modern first-line HAART.

scientific article published on 23 January 2013

Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism

scientific article

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen

scientific article published on 28 January 2016

Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

scientific article published in December 2002

Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial Data

scientific article

Kaposi's sarcoma herpesvirus and HIV-1 seroprevalences in prostitutes in Djibouti

article

Large Sample Theory for Schemper's Measures of Explained Variation in the Cox Regression Model

Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial

scientific article published on 13 August 2009

Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study ⬇️

scientific article published on December 7, 2011

Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy

scientific article published on 16 August 2010

Maraviroc Intensification of Stable Antiviral Therapy in HIV-1–Infected Patients With Poor Immune Restoration

article

Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individuals

scientific article published in September 2013

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

scientific article published on January 2000

National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation

scientific article

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism

scientific article

Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.

scientific article published on 15 October 2002

Note on the role of the placebo group in the short-term and long-term hazard ratio model

scientific article published on 01 September 2020

On the Use of Magnitude of Reduction in HIV-1 RNA in Clinical Trials: Statistical Analysis and Potential Biases

article

On the comparison of artificial network and interpretation systems based on genotype resistance mutations in HIV-1-infected patients

scientific article published in October 2006

On the use of auxiliary data to estimate the survival function and its variance: an application to acquired immunodeficiency syndrome.

scientific article published on August 1996

Patients with HIV-1 RNA below 1000 copies/ml after 48 weeks on dual nucleoside combination therapy

article

Pattern and evolution of the prescription of olanzapine during one year: Results of the cohort study ECOL

scientific article published on 2 June 2008

Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection

scientific article published on 21 December 2006

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen

scientific article

Predictive capability of proportional hazards regression.

scientific article

Predictive strength of Jonckheere's test for trend: an application to genotypic scores in HIV infection

article

Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing

scientific article published on 01 September 2018

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses

scientific article published on 29 January 2013

Prospective one-year bone loss in treatment-naïve HIV+ men and women on single or multiple drug HIV therapies

scientific article published on 26 January 2011

Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy

scientific article published on 18 May 2009

Quantification of the Prentice Criteria for Surrogate Endpoints

scientific article published on 01 March 2006

Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine

scientific article published on 17 February 2010

Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients

scientific article published on 01 May 2019

Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.

scientific article

Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy

scientific article published on 2 December 2013

Risk Factors of Chronic Kidney Disease in HIV-infected Patients

article

Risk factors for raltegravir resistance development in clinical practice

article

Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.

scientific article published on 28 July 2014

Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set

scientific article

Some current issues in the design of HIV noninferiority trials

scientific article

Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials

scientific article

Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.

scientific article published on 28 September 2012

Tenofovir and changes in renal function

scientific article published in February 2010

The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial

scientific article published on 01 May 2019

Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort

article

Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients

scientific article published on 14 July 2008

Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies

scientific article published on 01 November 2018

Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination

scientific article published on 26 May 2016

Weighted Kaplan-Meier estimators motivating to estimate HIV-1 RNA reduction censored by a limit of detection

scientific article published on 24 January 2020

List of works by Philippe Flandre

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure

A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study

A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients

Accuracy of predictive ability measures for survival models.

Analyzing Plasma HIV-1 RNA Measurements as Multiple Recurrent Events in Clinical Trials

Anti-gp41 antibody levels reflect HIV viral suppression and cellular reservoir in long-term antiretroviral-treated trial participants

Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study.

Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma

Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 Substudy

Choice of effect measure in HIV randomized trials.

Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients

Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach

Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy

Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load

Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).

Comparison of 48-week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimens: a systematic review and network meta-analysis

Confirmation of the low clinical effect of human herpesvirus-6 and -7 infections after renal transplantation

Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes

Design of HIV noninferiority trials ⬇️

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey

Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets

Discussion by O'Quigley and Flandre

Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine

Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group?

E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure

Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study

Effect of antiretroviral drugs on the quality of semen

Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.

Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data

Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen

Estimating and comparing reduction in HIV-1 RNA in clinical trials using methods for interval censored data

Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study

Evidence for a major gene controlling susceptibility to tegumentary leishmaniasis in a recently exposed Bolivian population

Factors Associated With Virological Failure in HIV-1–Infected Patients Receiving Darunavir/Ritonavir Monotherapy

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy

Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir

Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial

Final analysis of the Trilège induction-maintenance trial: results at 18 months

Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).

Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc

HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes

Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml

Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial

Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients

Impact of pre-therapy viral load on virological response to modern first-line HAART.

Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen

Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial Data

Kaposi's sarcoma herpesvirus and HIV-1 seroprevalences in prostitutes in Djibouti

Large Sample Theory for Schemper's Measures of Explained Variation in the Cox Regression Model

Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial

Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study ⬇️

Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy

Maraviroc Intensification of Stable Antiviral Therapy in HIV-1–Infected Patients With Poor Immune Restoration

Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individuals

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism

Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.

Note on the role of the placebo group in the short-term and long-term hazard ratio model

On the Use of Magnitude of Reduction in HIV-1 RNA in Clinical Trials: Statistical Analysis and Potential Biases

On the comparison of artificial network and interpretation systems based on genotype resistance mutations in HIV-1-infected patients

On the use of auxiliary data to estimate the survival function and its variance: an application to acquired immunodeficiency syndrome.

Patients with HIV-1 RNA below 1000 copies/ml after 48 weeks on dual nucleoside combination therapy

Pattern and evolution of the prescription of olanzapine during one year: Results of the cohort study ECOL

Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen

Predictive capability of proportional hazards regression.

Predictive strength of Jonckheere's test for trend: an application to genotypic scores in HIV infection

Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses